Plain-English translation of NCT07350863 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CXCR4/CCR9 CAR-T (U69), which uses your own immune cells that have been specially engineered in the lab to recognize and fight T-cell acute lymphoblastic leukemia or lymphoma. The medication is designed to target cancer cells that have specific markers on their surface. Researchers want to find out if this treatment is safe and whether it can help patients whose cancer has come back or stopped responding to other therapies.
Most patients with relapsed or refractory T-cell leukemia or lymphoma have very limited treatment options, and their cancer often does not respond well to standard chemotherapy. This trial exists to see if this new engineered immune cell therapy can offer hope to patients who have run out of other effective options.
You likely qualify if…
You likely don't qualify if…
First, you will undergo screening tests including blood work and biopsies to confirm your diagnosis and check that you are healthy enough for the study. If you qualify, your own immune cells will be collected through a process called apheresis. These cells will then be sent to a lab where they are engineered to recognize your cancer. After the cells are ready, you will return to the hospital to receive the medication as a single intravenous infusion. You will then be monitored closely for safety and effectiveness, with follow-up visits continuing for 2 years after treatment, and long-term follow-up extending up to 15 years.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China